Earlier this month, the National Institute for Health and Care Excellence (NICE), which stipulates which medical interventions are covered by England and Wales’ National Health Service (NHS), issued a statement that effectively brings Janssen’s ambitions to have its esketamine nasal spray (Spravato) product for treatment-resistant depression (TRD) reimbursed by the NHS in the UK’s most populous…
